Plain language notes on what each compound is studied for. No protocols, no advice. Independent research encouraged. All products supplied for research use only.
A newer triple agonist engaging GLP-1, GIP, and glucagon receptors simultaneously. Studied in research models for its effects on appetite signaling and metabolic pathways. One of the most discussed compounds in current metabolic research.
Dual GIP/GLP-1 agonist and the active compound in Mounjaro and Zepbound. Well-studied with an established research profile. Increasingly favored in research for its dual-receptor approach and tolerability data.
Long-acting amylin analogue studied for satiety signaling and gastric emptying pathways. Often explored in combination with semaglutide in research settings. Amylin receptor targeting distinguishes it from GLP-1 agonists.
BodhiPep's signature cosmetic and soft-tissue stack. GHK-Cu brings copper peptide skin and collagen signaling. BPC-157 and TB-500 add tissue remodeling and repair cues.
The classic recovery pair. BPC-157 studied for vascular signaling and tissue remodeling. TB-500 for actin dynamics and cell migration. Frequently explored together in preclinical models focused on repair and recovery pathways.
Pentadecapeptide with one of the most studied profiles in tissue research. Explored for vascular signaling, gut lining support, and joint-adjacent tissue remodeling. Stable, well-characterized, and widely referenced in preclinical literature.
Synthetic fragment related to thymosin beta-4. Investigated for effects on actin modulation, cell migration, and systemic repair signaling. Popular in recovery-focused research for its broad tissue distribution in studies.
Core redox coenzyme central to mitochondrial energy pathways. Studied extensively for its role in sirtuin activity, DNA repair signaling, and cellular energy metabolism.
Tetrapeptide with a long research track record in aging biology. Studied for telomere-related pathways and cellular stress responses. Typically explored in short, periodic research cycles in the longevity literature.
Mitochondria-derived peptide encoded in mitochondrial DNA. Explored for metabolic homeostasis signaling and exercise-mimetic responses in research models.
GHRH analogue with FDA precedent (Egrifta). Studied for growth hormone axis stimulation and visceral lipid pathway effects. Also researched for cognitive function and GH pulse optimization in aging models.
Selective ghrelin receptor agonist studied for GH pulse dynamics. Known in research for its selectivity and minimal effect on cortisol and prolactin compared to other secretagogues.
Copper tripeptide with extensive cosmetic research literature. Studied for skin appearance, collagen signaling, hair follicle support, and anti-inflammatory pathways. Core component of the Glow70 stack.
Copper peptide complex studied specifically for hair follicle signaling. Frequently used in topical cosmetic research and formulation testing. Often combined with GHK-Cu in hair-focused research protocols.
Tuftsin-derived anxiolytic peptide developed in Russian research. Studied for stress response modulation and cognitive clarity without sedation. Well-characterized in Eastern European literature for nootropic and anxiolytic pathways.
ACTH(4-7) analogue developed for neuroprotective research. Studied for neurotrophic signaling, BDNF-related pathways, and cognitive enhancement in models. Also used in stroke and neurological injury research contexts.
Melanocortin receptor agonist (bremelanotide) studied for central arousal signaling. Works through CNS pathways rather than vascular mechanisms. FDA-approved analogue exists (Vyleesi).
All products supplied for research purposes only. BodhiPep does not provide protocols, usage guidance, or medical advice. Independent study from reputable sources is always encouraged.
We have access to an extensive list of peptides and hormones beyond what is listed here. Text or email Bodhi directly to ask about availability and pricing.
For order questions or anything not covered here, text or email Bodhi at 512-886-7286.